Use of selective laser trabeculoplasty as an alternative in patients who developed ocular hypertension after intravitreal dexamethasone implants: a series of 35 eyes.
Dexamethasone intravitreal implant (DEXi)
Intraocular pressure (IOP)
Ocular hypertension (OHT)
Selective laser trabeculoplasty (SLT)
Steroid-induced
Journal
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
04
04
2022
accepted:
27
05
2022
revised:
22
05
2022
pubmed:
7
6
2022
medline:
22
10
2022
entrez:
6
6
2022
Statut:
ppublish
Résumé
Steroid-induced ocular hypertension (OHT) occurs in about a third of cases after dexamethasone implant (DEXi) intravitreal injection (IVI), for which treatment discontinuation may be required. The aim of this study was to assess the benefit of selective laser trabeculoplasty (SLT) in patients who developed transient OHT after DEXi injection to prevent subsequent steroid-induced OHT peaks during reinjections. A real-life, retrospective, and observational study was conducted to assess the intraocular pressure (IOP) after SLT in steroid responders after DEXi injection (IOP > 21 mmHg). Were analyzed: IOP 1 and 2 months after SLT, maximum IOP (IOP Thirty-five eyes of 29 patients were included. The mean macular edema follow-up duration was 38.4 ± 28.4 months. SLT was performed after a mean number of 6.3 ± 4.7 DEXi IVIs. After SLT, the IOP The use of 180° SLT in this indication could be an effective therapeutic alternative to control steroid-induced OHT and safely continue DEXi injections.
Identifiants
pubmed: 35665853
doi: 10.1007/s00417-022-05725-3
pii: 10.1007/s00417-022-05725-3
doi:
Substances chimiques
Dexamethasone
7S5I7G3JQL
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3665-3673Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Francois J (1954) Cortisone and eye strain. Ann Ocul (Paris) 187:805–816
Lewis JM, Priddy T, Judd J et al (1988) Intraocular pressure response to topical dexamethasone as a predictor for the development of primary open-angle glaucoma. Am J Ophthalmol 106:607–612. https://doi.org/10.1016/0002-9394(88)90595-8
doi: 10.1016/0002-9394(88)90595-8
pubmed: 3189477
Malclès A, Dot C, Voirin N et al (2017) Safety of intravitreal dexamethasone implant (Ozurdex): the SAFODEX study. Incidence and risk factors of ocular hypertension. Retina 37:1352–1359. https://doi.org/10.1097/IAE.0000000000001369
doi: 10.1097/IAE.0000000000001369
pubmed: 27768641
Dot C, El Chehab H, Russo A, Agard E (2015) Hypertonie oculaire après injections intra-vitréennes de corticoïdes, actualisation des connaissances en 2015. J Fr Ophtalmol 38:656–664. https://doi.org/10.1016/j.jfo.2015.03.002
doi: 10.1016/j.jfo.2015.03.002
pubmed: 26099427
Johnson D (1997) Ultrastructural changes in the trabecular meshwork of human eyes treated with corticosteroids. Arch Ophthalmol 115:375. https://doi.org/10.1001/archopht.1997.01100150377011
doi: 10.1001/archopht.1997.01100150377011
pubmed: 9076211
Razeghinejad MR, Katz LJ (2012) Steroid-induced iatrogenic glaucoma. Ophthalmic Res 47:66–80. https://doi.org/10.1159/000328630
doi: 10.1159/000328630
pubmed: 21757964
Armaly MF (1963) Effect of corticosteroids on intraocular pressure and fluid dynamics: i. The effect of dexamethasone* in the Normal Eye. Arch Ophthalmol 70:482. https://doi.org/10.1001/archopht.1963.00960050484010
Armaly MF (1963) Effect of corticosteroids on intraocular pressure and fluid dynamics: ii.he effect of dexamethasone in the glaucomatous eye. Arch Ophthalmol 70:492. https://doi.org/10.1001/archopht.1963.00960050494011
Armaly MF, Becker B (1965) Intraocular pressure response to topical corticosteroids. Fed Proc 24:1274–1278
pubmed: 5853148
Lowder C (2011) Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 129:545. https://doi.org/10.1001/archophthalmol.2010.339
doi: 10.1001/archophthalmol.2010.339
pubmed: 21220619
Bellocq D, Korobelnik J-F, Burillon C et al (2015) Effectiveness and safety of dexamethasone implants for post-surgical macular oedema including Irvine-Gass syndrome: the EPISODIC study. Br J Ophthalmol 99:979–983. https://doi.org/10.1136/bjophthalmol-2014-306159
doi: 10.1136/bjophthalmol-2014-306159
pubmed: 25583283
Haller JA, Bandello F, Belfort R et al (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118:2453–2460. https://doi.org/10.1016/j.ophtha.2011.05.014
doi: 10.1016/j.ophtha.2011.05.014
pubmed: 21764136
Rezkallah A, Mathis T, Abukhashabah A et al (2021) Long-term incidence and risk factors of ocular hypertension following dexamethasone-implant injections : the SAFODEX-2 Study. Retina 41:1438–1445. https://doi.org/10.1097/IAE.0000000000003080
doi: 10.1097/IAE.0000000000003080
pubmed: 33315814
Poli M, Denis P, Dot C, Nordmann J-P (2017) Conduite à tenir face au risque d’hypertonie oculaire après injection intra-vitréenne. J Fr Ophtalmol 40:e77–e82. https://doi.org/10.1016/j.jfo.2017.01.003
doi: 10.1016/j.jfo.2017.01.003
pubmed: 28284658
Bozkurt E, Kara N, Yazici AT et al (2011) Prophylactic selective laser trabeculoplasty in the prevention of intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Am J Ophthalmol 152:976-981.e2. https://doi.org/10.1016/j.ajo.2011.05.027
doi: 10.1016/j.ajo.2011.05.027
pubmed: 21861972
Maleki A, Swan RT, Lasave AF et al (2016) Selective laser trabeculoplasty in controlled uveitis with steroid-induced glaucoma. Ophthalmology 123:2630–2632. https://doi.org/10.1016/j.ophtha.2016.07.027
doi: 10.1016/j.ophtha.2016.07.027
pubmed: 27594199
Cohen S-Y, Kodjikian L, Devin F et al (2020) Avis d’experts : actualisation des bonnes pratiques des injections intravitréennes. Recommandations de la Société française d’ophtalmologie et de la Société française d’hygiène hospitalière. Journal Français d’Ophtalmologie 43:59–62. https://doi.org/10.1016/j.jfo.2019.11.002
doi: 10.1016/j.jfo.2019.11.002
pubmed: 31806256
European Glaucoma Society (2020) Terminology and guidelines for glaucoma, 5th edn. PubliComm, Savona
Maturi RK, Pollack A, Uy HS et al (2016) Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina 36:1143–1152. https://doi.org/10.1097/IAE.0000000000001004
doi: 10.1097/IAE.0000000000001004
pubmed: 26871523
Zhou Y, Pruet CM, Fang C, Khanna CL (2021) Selective laser trabeculoplasty in steroid-induced and uveitic glaucoma. Canadian J Ophthalmol S0008418221001769. https://doi.org/10.1016/j.jcjo.2021.05.006
Weinand FS, Althen F (2006) Long-term clinical results of selective laser trabeculoplasty in the treatment of primary open angle glaucoma. Eur J Ophthalmol 16:100–104. https://doi.org/10.1177/112067210601600116
doi: 10.1177/112067210601600116
pubmed: 16496252
Realini T, Shillingford-Ricketts H, Burt D, Balasubramani GK (2021) Long-term outcomes of selective laser trabeculoplasty for open-angle glaucoma in the Caribbean. Am J Ophthalmol 232:83–89. https://doi.org/10.1016/j.ajo.2021.06.012
doi: 10.1016/j.ajo.2021.06.012
pubmed: 34153267
Campochiaro PA, Brown DM, Pearson A et al (2011) Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 118:626-635.e2. https://doi.org/10.1016/j.ophtha.2010.12.028
doi: 10.1016/j.ophtha.2010.12.028
pubmed: 21459216